These cells stimulate T helper type 1 (Th1) helper cells that in

These cells stimulate T helper type 1 (Th1) helper cells that in turn elicit the production of cytotoxic T lymphocytes (CTL) [22]. These cytotoxic effector cells attack infected cells, resulting in resolution of the infection [23]. However, little is known about how to modulate these immune responses. Prophylactic vaccination. 

Vaccination p38 MAPK phosphorylation with VLPs gives rise to virus-neutralizing antibodies in serum. Vaccination by intramuscular injection of L1 VLPs has been shown to be highly immunogenic and well tolerated in Phase I trials [24–27]. Three randomized placebo-controlled Phase II trials with, respectively, a monovalent HPV16 vaccine, a bivalent HV16/18 vaccine and a quadrivalent HPV6/11/16/18 vaccine candidate have consistently demonstrated almost complete protection against persistent infection with the targeted HPV types [28–32]. Moreover, these trials confirmed Seliciclib order the safety of the vaccines and showed strong immunoresponses that were several orders of magnitude higher than those observed after natural infections. Two pharmaceutical companies [Merck Sharp & Dohme (MSD) and GlaxoSmithKline (GSK)] have completed large multi-centre Phase III vaccine trials

in all continents except Africa [33–35]. In addition, the National Cancer Institute (United States) is conducting a population-based trial in Costa Rica using the bivalent vaccine [36]. These Phase III trials demonstrated that vaccines protect against histologically confirmed high-grade cervical intraepithelial neoplasia (CIN) and adenocarcinoma in situ (AIS) associated with the targeted HPV types under the condition that subjects were not infected with one or more vaccine types at baseline [33–35]. Both vaccine formulations have a good safety profile. Tangeritin Neither has noted any therapeutic effect, as women who test positive for HPV DNA prior to vaccination show no protection against disease end-points associated with that type. Modest cross-protection to closely related high-risk types HPV

31, 33, 45 was found with bivalent vaccine [Cervarix(R)][37] and also to some extent with the quadrivalent vaccine [Gardasil(R)][38,39]. Therapeutic HPV vaccines.  Development of cervical precursors, their maintenance and progression to invasive cancer requires the continued intracellular expression of the viral oncoproteins E6 and E7 [40,41]. Therefore, therapeutic vaccines have been directed towards stimulating T cell responses against these viral early oncogenes. The approaches include administration of peptide antigens or recombinant proteins, plasmid DNA vaccines, viral vector vaccines and administration of E7-pulsed dendritic cells, but despite being variably immunogenic have not shown an impact upon invasive cancer but appear to induce some degree of clearance of cancer precursors or anogenital warts [23,42–44].

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>